obÌåÓý

Introduction

The routine COVID-19 vaccination schedule (i.e., for people who are not moderately or severely immunocompromised) is detailed in Table 1. The recommended vaccine and number of 2024–2025 COVID-19 vaccine doses are based on age and vaccination history. COVID-19 vaccination guidance for people who are moderately or severely immunocompromised is detailed in Table 2.

Table 1: Routine COVID-19 vaccination schedule, October 31, 2024

1a: Ages 6 months–4 years

^{*_{COVID-19 vaccination history refers to all doses of COVID-19 vaccine from any manufacturer received before the availability of the 2024–2025 COVID-19 vaccines and includes original, bivalent, and 2023–2024 COVID-19 vaccines.}}

^{†_{Dosage for Moderna: 0.25 mL/25 ug; dosage for Pfizer-BioNTech: 0.3 mL/3 ug.}}

^{‡_{An 8-week interval between the first and second COVID-19 vaccine (Moderna and Pfizer-BioNTech) doses might be optimal for some people as it might reduce the rare risk of myocarditis and pericarditis associated with these vaccines.}}

1b: Ages 5-11 years

<sup>*<sub>Children who transition from age 4 years to age 5 years during the initial vaccination series should receive 1 dose of vaccine from the same manufacturer at the dosage for children ages 5–11 years on or after turning age 5 years:
- Moderna: 1 dose of 2024–2025 Moderna (0.25 mL/25 ug) 4–8 weeks after the first dose; there is no dosage change.
- Pfizer-BioNTech: 1 dose of 2024–2025 Pfizer-BioNTech (0.3 mL/10 ug). If the 10 ug dose is the second dose, administer 3–8 weeks after the first dose; if it is the third dose, administer at least 8 weeks after the second dose.
- NOTE: If more than 8 weeks have elapsed since receipt of the last dose of mRNA COVID-19 vaccine at the dosage for children ages 6 months–4 years, any 2024–2025 mRNA COVID-19 vaccine (i.e., Moderna or Pfizer-BioNTech) may be administered at the dosage for children ages 5–11 years.</sub></sup>

^{†_{COVID-19 vaccination history refers to all doses of COVID-19 vaccine from any manufacturer received before the availability of the 2024–2025 COVID-19 vaccines and includes original, bivalent, and 2023–2024 COVID-19 vaccines.}}

^{‡_{Dosage for Moderna: 0.25 mL/25 ug; dosage for Pfizer-BioNTech: 0.3 mL/10 ug.}}

1c: Ages 12-64 years

^{*_{COVID-19 vaccination history refers to all doses of COVID-19 vaccine from any manufacturer received before the availability of the 2024–2025 COVID-19 vaccines and includes original, bivalent, and 2023–2024 COVID-19 vaccines.}}

^{†_{People ages 18-64 years who received 1 or more doses of Janssen COVID-19 Vaccine should receive 1 dose of any 2024–2025 COVID vaccine.}}

^{‡_{Dosage for Moderna: 0.5 mL/50 ug; dosage for Novavax: 0.5 mL/5 ug rS protein and 50 ug Matrix-M adjuvant; dosage for Pfizer-BioNTech: 0.3 mL/30 ug.}}

^{§_{An 8-week interval between the first and second COVID-19 vaccine (Moderna, Novavax, Pfizer-BioNTech) doses might be optimal for some people as it might reduce the rare risk of myocarditis and pericarditis associated with these vaccines.}}

^{¶_{If more than 8 weeks have elapsed since receipt of the first dose of Novavax, any 2024–2025 COVID-19 vaccine (i.e., Moderna, Novavax, or Pfizer-BioNTech) may be administered.}}

1d: Ages 65 years and older

^{*_{COVID-19 vaccination history refers to all doses of COVID-19 vaccine from any manufacturer received before the availability of the 2024–2025 COVID-19 vaccines and includes original, bivalent, and 2023–2024 COVID-19 vaccines.}}

^{†_{People ages 65 years and older who received 1 or more doses of Janssen COVID-19 Vaccine should receive a first dose of any 2024–2025 COVID-19 vaccine followed by a second dose of any 2024–2025 COVID-19 vaccine 6 months (minimum interval 2 months) after the first dose.}}

^{‡_{Dosage for Moderna: 0.5 mL/50 ug; dosage for Novavax: 0.5 mL/5 ug rS protein and 50 ug Matrix-M adjuvant; dosage for Pfizer-BioNTech: 0.3 mL/30 ug.}}

^{§_{An 8-week interval between the first and second COVID-19 vaccine (Moderna, Novavax, and Pfizer-BioNTech) doses might be optimal for some people as it might reduce the rare risk of myocarditis and pericarditis associated with these vaccines.}}

^{¶_{If more than 8 weeks have elapsed since receipt of the first dose of Novavax, any 2024–2025 COVID-19 vaccine (i.e., Moderna, Novavax, or Pfizer-BioNTech) may be administered.}}

Considerations for extended intervals for COVID-19 vaccine doses

An 8-week interval between the first and second mRNA COVID-19 vaccine (Moderna, Pfizer-BioNTech) doses and between the first and second doses of Novavax COVID-19 Vaccine might be optimal for some people as it might reduce the rare risk of myocarditis and pericarditis associated with these COVID-19 vaccines.

While for myocarditis and pericarditis has been observed among mRNA COVID-19 vaccine recipients, particularly in males ages 12–39 years (see COVID-19 vaccination and myocarditis and pericarditis for additional information). were identified in clinical trials of Novavax COVID-19 Vaccine and through passive surveillance during post-authorization use outside the United States.

Under the current COVID-19 vaccination schedule (Table 1), the extended interval consideration applies only to people vaccinated under the routine schedule (i.e., not moderately or severely immunocompromised):

• Ages 6 months–4 years, depending on their vaccination history
• Ages 12 years–64 years and receiving a 2-dose Novavax series

The minimum interval between the first and second doses continues to be recommended for:

• People who are moderately or severely immunocompromised
• People ages 65 years and older receiving Novavax vaccine
• Situations when the fullest possible protection needs to be achieved sooner (e.g., increased concern about an individual's higher risk for severe disease)